TY - JOUR
T1 - Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
AU - Mast, Fred D.
AU - Fridy, Peter C.
AU - Ketaren, Natalia E.
AU - Wang, Junjie
AU - Jacobs, Erica Y.
AU - Olivier, Jean Paul
AU - Sanyal, Tanmoy
AU - Molloy, Kelly R.
AU - Schmidt, Fabian
AU - Rutkowska, Magdalena
AU - Weisblum, Yiska
AU - Rich, Lucille M.
AU - Vanderwall, Elizabeth R.
AU - Dambrauskas, Nicholas
AU - Vigdorovich, Vladimir
AU - Keegan, Sarah
AU - Jiler, Jacob B.
AU - Stein, Milana E.
AU - Olinares, Paul Dominic B.
AU - Herlands, Louis
AU - Hatziioannou, Theodora
AU - Sather, D. Noah
AU - Debley, Jason S.
AU - Fenyö, David
AU - Sali, Andrej
AU - Bieniasz, Paul D.
AU - Aitchison, John D.
AU - Chait, Brian T.
AU - Rout, Michael P.
N1 - Publisher Copyright:
© Mast et al.
PY - 2021/12
Y1 - 2021/12
N2 - The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic antibodies and urgently demands powerful new therapeutics that can resist viral escape. We therefore generated a large nanobody repertoire to saturate the distinct and highly conserved available epitope space of SARS-CoV-2 spike, including the S1 receptor binding domain, N-terminal domain, and the S2 subunit, to identify new nanobody binding sites that may reflect novel mechanisms of viral neutralization. Structural mapping and functional assays show that indeed these highly stable monovalent nanobodies potently inhibit SARS-CoV-2 infection, display numerous neutralization mechanisms, are effective against emerging variants of concern, and are resistant to mutational escape. Rational combinations of these nanobodies that bind to distinct sites within and between spike subunits exhibit extraordinary synergy and suggest multiple tailored therapeutic and prophy-lactic strategies.
AB - The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic antibodies and urgently demands powerful new therapeutics that can resist viral escape. We therefore generated a large nanobody repertoire to saturate the distinct and highly conserved available epitope space of SARS-CoV-2 spike, including the S1 receptor binding domain, N-terminal domain, and the S2 subunit, to identify new nanobody binding sites that may reflect novel mechanisms of viral neutralization. Structural mapping and functional assays show that indeed these highly stable monovalent nanobodies potently inhibit SARS-CoV-2 infection, display numerous neutralization mechanisms, are effective against emerging variants of concern, and are resistant to mutational escape. Rational combinations of these nanobodies that bind to distinct sites within and between spike subunits exhibit extraordinary synergy and suggest multiple tailored therapeutic and prophy-lactic strategies.
UR - http://www.scopus.com/inward/record.url?scp=85122147822&partnerID=8YFLogxK
U2 - 10.7554/eLife.73027
DO - 10.7554/eLife.73027
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34874007
AN - SCOPUS:85122147822
SN - 2050-084X
VL - 10
JO - eLife
JF - eLife
M1 - e73027
ER -